INS and type 2 diabetes mellitus: Our study demonstrates that when SGLT 2 inhibitors were added at any stage of the disease in the real world scenario, in patients with uncontrolled T2D, there is a clinical and statistically significant improvement in glycemic control, weight loss and reduction in blood pressure in our patients, as has been demonstrated in the landmark studies with SGLT 2 inhibitors.14,15 This class of drug improves glycemic function independent of insulin secretion.